Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:42 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: | NSE:

Beta Drugs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,383.90Fairly Valued by 8.97%vs CMP ₹1,270.00

P/E (29.9) × ROE (25.9%) × BV (₹219.00) × DY (2.00%)

₹776.89Overvalued by 38.83%vs CMP ₹1,270.00
MoS: -63.5% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,790.2123%Under (+41%)
Graham NumberEarnings₹455.0317%Over (-64.2%)
Earnings PowerEarnings₹153.3411%Over (-87.9%)
DCFCash Flow₹872.7611%Over (-31.3%)
Net Asset ValueAssets₹218.087%Over (-82.8%)
EV/EBITDAEnterprise₹550.639%Over (-56.6%)
Earnings YieldEarnings₹420.207%Over (-66.9%)
ROCE CapitalReturns₹666.669%Over (-47.5%)
Revenue MultipleRevenue₹357.226%Over (-71.9%)
Consensus (9 models)₹776.89100%Overvalued
Key Drivers: EPS CAGR 29.4% lifts DCF — verify sustainability. | Wide model spread (₹153–₹1,790) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 29.4%

*Investments are subject to market risks

Investment Snapshot

78
Beta Drugs Ltd scores 78/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health89/100 · Strong
ROCE 27.0% ExcellentROE 25.9% ExcellentD/E 0.21 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.24% (6mo) Slight increaseDII holding up 1.73% MF buyingPromoter decreased by 1.83% Caution
Earnings Quality50/100 · Moderate
OPM stable around 21% Steady
Quarterly Momentum90/100 · Strong
Revenue (4Q): +55% YoY AcceleratingProfit (4Q): +30% YoY Strong
Industry Rank100/100 · Strong
P/E 29.9 vs industry 53.8 Cheaper than peersROCE 27.0% vs industry 16.4% Above peersROE 25.9% vs industry 15.2% Above peers3Y sales CAGR: 25% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:42 am

Market Cap 1,287 Cr.
Current Price 1,270
Intrinsic Value₹776.89
High / Low 2,000/990
Stock P/E29.9
Book Value 219
Dividend Yield0.00 %
ROCE27.0 %
ROE25.9 %
Face Value 10.0
PEG Ratio1.02

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Beta Drugs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Beta Drugs Ltd 1,287 Cr. 1,270 2,000/99029.9 2190.00 %27.0 %25.9 % 10.0
Jagsonpal Pharmaceuticals Ltd 1,243 Cr. 186 302/15529.2 37.91.35 %23.0 %18.6 % 2.00
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
Hester Biosciences Ltd 1,162 Cr. 1,366 2,350/1,23928.4 3970.51 %9.71 %9.18 % 10.0
Venus Remedies Ltd 1,151 Cr. 861 950/28615.1 4450.00 %11.1 %7.16 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Beta Drugs Ltd

Quarterly Result

MetricSep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 474451658896112115141154180182204
Expenses 3736415168738688108127141146163
Operating Profit 981114202327263327393641
OPM % 20%19%21%22%23%24%24%23%23%18%22%20%20%
Other Income 0000000011206
Interest 1211111111257
Depreciation 2234345654678
Profit before tax 7579161821202722332432
Tax % 27%14%21%30%28%27%25%25%25%25%25%26%25%
Net Profit 5457121316152017241824
EPS in Rs 5.074.255.136.4811.6312.9515.6714.7319.6716.4024.2017.8123.70

Last Updated: January 2, 2026, 7:02 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 2:16 pm

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 516691116184227296362
Expenses 41547391141174236288
Operating Profit 912182543536075
OPM % 19%18%20%21%23%23%20%21%
Other Income 00001112
Interest 11322237
Depreciation 23477101013
Profit before tax 78121634414957
Tax % 1%-2%21%27%28%25%25%26%
Net Profit 7891225313642
EPS in Rs 7.438.849.3311.6024.5830.4236.0842.02
Dividend Payout % 0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)14.29%12.50%33.33%108.33%24.00%16.13%16.67%
Change in YoY Net Profit Growth (%)0.00%-1.79%20.83%75.00%-84.33%-7.87%0.54%

Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:32%
3 Years:25%
TTM:23%
Compounded Profit Growth
10 Years:%
5 Years:37%
3 Years:23%
TTM:26%
Stock Price CAGR
10 Years:%
5 Years:87%
3 Years:36%
1 Year:12%
Return on Equity
10 Years:%
5 Years:26%
3 Years:27%
Last Year:26%

Last Updated: September 5, 2025, 12:45 am

Balance Sheet

Last Updated: January 7, 2026, 3:27 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 9910101010101010
Reserves 2432485983113148187211
Borrowings 8202317212015138146
Other Liabilities 9222831455582101121
Total Liabilities 5083107118158198254436488
Fixed Assets 1318444055636589112
CWIP 1150300000
Investments 000111000
Other Assets 35506374102135190347376
Total Assets 5083107118158198254436488

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 17081930233136
Cash from Investing Activity + -11-21-15-6-22-19-14-36
Cash from Financing Activity + 5129-8-1-2-7118
Net Cash Flow 12-925729118
Free Cash Flow 9-21-71310519-1
CFO/OP 181%1%47%75%69%44%52%48%

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow1.00-8.00-5.008.0022.0033.0045.00-63.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1041391281069010198103
Inventory Days 3710410210087106122127
Days Payable 81143119127123139145152
Cash Conversion Cycle 601001117953687579
Working Capital Days 5040567661738082
ROCE %18%21%22%36%34%33%27%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%64.90%
FIIs 0.29%0.29%0.32%0.32%0.32%0.90%1.16%1.15%0.90%0.90%0.90%1.14%
DIIs 0.04%0.04%0.02%0.02%0.06%0.12%0.16%0.17%0.17%0.26%0.29%1.90%
Public 32.94%32.93%32.93%32.92%32.87%32.25%31.95%31.95%32.20%32.11%32.07%32.07%
No. of Shareholders 1,4241,4511,7221,9282,1162,3232,5672,8823,0543,1393,1843,694

Shareholding Pattern Chart

No. of Shareholders

Beta Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 42.0237.9031.9525.8212.20
Diluted EPS (Rs.) 42.0237.9031.9525.8212.20
Cash EPS (Rs.) 54.4248.0842.7833.3719.34
Book Value[Excl.RevalReserv]/Share (Rs.) 195.25163.43127.8296.0571.37
Book Value[Incl.RevalReserv]/Share (Rs.) 195.25163.43127.8296.0571.37
Revenue From Operations / Share (Rs.) 358.96307.59236.24191.22120.79
PBDIT / Share (Rs.) 80.2863.8256.0545.2026.26
PBIT / Share (Rs.) 67.8953.6545.2237.6519.11
PBT / Share (Rs.) 56.4450.7142.7035.6816.59
Net Profit / Share (Rs.) 42.0237.9031.9525.8212.20
NP After MI And SOA / Share (Rs.) 42.0237.9031.9525.8212.20
PBDIT Margin (%) 22.3620.7423.7223.6321.73
PBIT Margin (%) 18.9117.4419.1419.6915.81
PBT Margin (%) 15.7216.4818.0718.6513.73
Net Profit Margin (%) 11.7012.3213.5213.5010.09
NP After MI And SOA Margin (%) 11.7012.3213.5213.5010.09
Return on Networth / Equity (%) 21.5223.1924.9926.8817.08
Return on Capital Employeed (%) 20.5430.4332.1033.2422.09
Return On Assets (%) 9.7214.3315.4815.729.97
Long Term Debt / Equity (X) 0.640.030.050.120.16
Total Debt / Equity (X) 0.670.060.130.170.21
Asset Turnover Ratio (%) 1.051.311.271.090.82
Current Ratio (X) 3.222.102.031.981.99
Quick Ratio (X) 2.641.511.541.521.53
Inventory Turnover Ratio (X) 6.614.174.165.704.47
Interest Coverage Ratio (X) 11.6021.7622.3122.8810.43
Interest Coverage Ratio (Post Tax) (X) 7.7213.9213.7214.075.85
Enterprise Value (Cr.) 1909.201168.47599.62542.92119.61
EV / Net Operating Revenue (X) 5.273.952.642.951.03
EV / EBITDA (X) 23.5619.0411.1312.494.74
MarketCap / Net Operating Revenue (X) 5.314.012.652.960.99
Price / BV (X) 9.767.554.905.891.68
Price / Net Operating Revenue (X) 5.314.012.652.960.99
EarningsYield 0.020.030.050.040.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 220.20 Cr. and Equity Capital is Rs. 10.09 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Nandpur, Baddi Himachal Pradesh 174101Contact not found
Management
NamePosition Held
Mr. Rahul BatraChairperson & Managing Director
Mr. Varun BatraJoint Managing Director
Mr. Ashutosh ShuklaWhole Time Director
Mr. Balwant SinghWhole Time Director
Mr. Ajay MahipalDirector
Mr. Manmohan KhannaIndependent Director
Mr. Rohit PartiIndependent Director
Mrs. Monica JainIndependent Director
Mr. Sanjay SehgalIndependent Director
Mr. Lalit Kumar WattsIndependent Director

FAQ

What is the intrinsic value of Beta Drugs Ltd and is it undervalued?

As of 10 April 2026, Beta Drugs Ltd's intrinsic value is ₹776.89, which is 38.83% lower than the current market price of ₹1,270.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (25.9 %), book value (₹219), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Beta Drugs Ltd?

Beta Drugs Ltd is trading at ₹1,270.00 as of 10 April 2026, with a FY2026-2027 high of ₹2,000 and low of ₹990. The stock is currently in the middle of its 52-week range. Market cap stands at ₹1,287 Cr..

How does Beta Drugs Ltd's P/E ratio compare to its industry?

Beta Drugs Ltd has a P/E ratio of 29.9, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Beta Drugs Ltd financially healthy?

Key indicators for Beta Drugs Ltd: ROCE of 27.0 % indicates efficient capital utilization; ROE of 25.9 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Beta Drugs Ltd profitable and how is the profit trend?

Beta Drugs Ltd reported a net profit of ₹42 Cr in Mar 2025 on revenue of ₹362 Cr. Compared to ₹25 Cr in Mar 2022, the net profit shows an improving trend.

Does Beta Drugs Ltd pay dividends?

Beta Drugs Ltd has a dividend yield of 0.00 % at the current price of ₹1,270.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Beta Drugs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports